This study undertakes an analysis of external sourcing of knowledge by biotechnology companies. It suggests that biotechnology companies need to be more realistic about R&D operational models in a context where technological changes are only incremental and companies based solely on single technology platforms are highly inefficient. It is argued that in order to build, preserve or enhance their knowledge creation capabilities in a fast changing environment, firms increasingly combine internal ‘‘core’’ capabilities with externally acquired ‘‘complementary’’ ones. Knowledge creation requires in reaching the right balance between exploration and exploitation. It consists of activities within the firm in order to create knowledge from its ...
Sweden is the fourth largest biotechnology country in Europe and Sweden has the highest number of bi...
Compared to large established firms, technology-based new firms (TBNF) seem well placed to produce b...
This study of the organization of the discovery function by large US pharmaceutical companies (LPCs)...
This study undertakes an analysis of external sourcing of knowledge by biotechnology companies. It s...
The article aims to present a thorough research on the perceptions and opinions of the Romanian man...
The advent of born-global bio-tech firms signal the genesis of a new business model that is emerging...
This study examines decision making in large and small firms undertaking biotechnology innovation an...
© 2006 Dr. John P. MorganGlobalization and the exponential growth of information on genetics and DNA...
Technological progress in the biological sciences is now advancing across such a wide range and at s...
Knowledge diffusion and knowledge externalities are important sources of economic growth. It is beco...
Innovation and firm creation are enablers of industry development, especially in industries that are...
In this ever changing and challenging business landscape characterized by rapid and continuous techn...
We draw from documented characteristics of the biopharmaceutical industry to construct a model where...
This paper offers a new interpretive perspective to investigate factors of researchers productivity,...
We explore how an incumbent firm's internal knowledge and organization structure influences its stra...
Sweden is the fourth largest biotechnology country in Europe and Sweden has the highest number of bi...
Compared to large established firms, technology-based new firms (TBNF) seem well placed to produce b...
This study of the organization of the discovery function by large US pharmaceutical companies (LPCs)...
This study undertakes an analysis of external sourcing of knowledge by biotechnology companies. It s...
The article aims to present a thorough research on the perceptions and opinions of the Romanian man...
The advent of born-global bio-tech firms signal the genesis of a new business model that is emerging...
This study examines decision making in large and small firms undertaking biotechnology innovation an...
© 2006 Dr. John P. MorganGlobalization and the exponential growth of information on genetics and DNA...
Technological progress in the biological sciences is now advancing across such a wide range and at s...
Knowledge diffusion and knowledge externalities are important sources of economic growth. It is beco...
Innovation and firm creation are enablers of industry development, especially in industries that are...
In this ever changing and challenging business landscape characterized by rapid and continuous techn...
We draw from documented characteristics of the biopharmaceutical industry to construct a model where...
This paper offers a new interpretive perspective to investigate factors of researchers productivity,...
We explore how an incumbent firm's internal knowledge and organization structure influences its stra...
Sweden is the fourth largest biotechnology country in Europe and Sweden has the highest number of bi...
Compared to large established firms, technology-based new firms (TBNF) seem well placed to produce b...
This study of the organization of the discovery function by large US pharmaceutical companies (LPCs)...